pioglitazone has been researched along with Uremia in 1 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Uremia: A clinical syndrome associated with the retention of renal waste products or uremic toxins in the blood. It is usually the result of RENAL INSUFFICIENCY. Most uremic toxins are end products of protein or nitrogen CATABOLISM, such as UREA or CREATININE. Severe uremia can lead to multiple organ dysfunctions with a constellation of symptoms.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to investigate the relationship between accelerated atherosclerosis (AS) and the balance of regulatory/effector T cells (Treg/Teff) in uremic apolipoprotein E knockout (apoE-/-) mice, and the effect of pioglitazone on uremic AS and possible mechanisms." | 3.77 | Antiatherogenic effect of pioglitazone on uremic apolipoprotein E knockout mice by modulation of the balance of regulatory and effector T cells. ( Chen, T; Kishimoto, C; Liang, X; Liu, W; Liu, Y; Shen, Y; Tian, Y; Wang, L; Wu, Y; Xiao, Y; Yin, A; Yuan, Z; Zhao, Y, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shen, Y | 1 |
| Yuan, Z | 1 |
| Yin, A | 1 |
| Liu, Y | 1 |
| Xiao, Y | 1 |
| Wu, Y | 1 |
| Wang, L | 1 |
| Liang, X | 1 |
| Zhao, Y | 1 |
| Tian, Y | 1 |
| Liu, W | 1 |
| Chen, T | 1 |
| Kishimoto, C | 1 |
1 other study available for pioglitazone and Uremia
| Article | Year |
|---|---|
Antiatherogenic effect of pioglitazone on uremic apolipoprotein E knockout mice by modulation of the balance of regulatory and effector T cells.
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Body Weight; Cytokines; Hypoglycemic Agents; Mal | 2011 |